Eli Lilly and Company will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025. Lilly will also conduct a conference call that day with the investment ...

Online master’s degrees in engineering and education from Purdue again rank among the nation’s finest. Four of Pur ...

London-based Gresham House Ventures, a growth equity investor, announced that it has committed a €4.25M investment in Mobility Mojo.

The major U.S. index futures are currently pointing to a higher open on Wednesday, with stocks likely to add to the gains posted in ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Shares of pharmaceutical giant Eli Lilly have been falling in recent months. The company updated its guidance last week, and investors weren't impressed. It could be a tough year for Eli Lilly ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.